ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. has announced that it has received approval from the National Medical Products Administration (NMPA) of the People's Republic of China to initiate a clinical trial for their investigational new drug, IMC-003/IMM72. The trial aims to explore the treatment of pulmonary arterial hypertension (PAH) using this new generation activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, which has been enhanced through genetic engineering for improved activity and quality attributes. ImmuneOnco Biopharmaceuticals holds the global intellectual property rights and development and commercialization rights for IMC-003/IMM72. This approval marks a significant milestone in the company's ongoing efforts to advance its biopharmaceutical innovations.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。